You are viewing: UK Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The UK Nuclear Medicine Market was valued at $455.4 Million in 2025 and projected to reach to $971.1 Million by 2030, representing a compound annual growth rate of 16.4%. The UK nuclear medicine market is positioned for significant expansion through 2030, driven by sustained NHS investment and modernization of diagnostic imaging capabilities across the country.

UK Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Nuclear Medicine Market Trends and Insights

  • The UK's advanced healthcare infrastructure and increasing adoption of diagnostic imaging technologies are driving this accelerated growth trajectory.
  • The UK benefits from strong NHS investment in nuclear medicine capabilities, supporting both diagnostic and therapeutic applications across oncology, cardiology, and neurology specialties. The UK nuclear medicine sector is characterized by rising demand for personalized medicine and targeted therapies, which are propelling market expansion.
  • Between 2025 and 2030, the UK is expected to see significant investment in radiopharmaceutical development and imaging equipment modernization.
  • The UK's regulatory framework and clinical excellence standards position it as a leader in nuclear medicine innovation within Europe, attracting both domestic and international market participants..

Key Market Statistics

  • CAGR (2025-2030) 16.4% CAGR
  • Market Size, 2025 ~USD 455.4 Million
  • Forecast, 2030 ~USD 971.1 Million
  • Country UK

UK Nuclear Medicine Market Overview

Market Valuation Growth :

The UK nuclear medicine market is valued at $455.4 million in 2025, with projections to reach $971.1 million by 2030, representing a robust 16.4% CAGR over the forecast period.

NHS Investment Drive :

Strong NHS funding and strategic investment in nuclear medicine infrastructure across UK hospitals are accelerating adoption of diagnostic imaging technologies and therapeutic applications.

Advanced Healthcare Infrastructure :

The UK's mature healthcare system, coupled with regulatory support and established clinical protocols, creates a favorable environment for nuclear medicine expansion and innovation.

Diagnostic & Therapeutic Expansion :

Growing demand for both diagnostic imaging and therapeutic nuclear medicine procedures is driving market growth, supported by increasing clinical evidence and patient awareness.

UK Nuclear Medicine Market Dynamics

  • Healthcare providers are increasingly recognizing the clinical value of nuclear medicine in oncology, cardiology, and neurology applications, leading to higher adoption rates.
  • The UK's regulatory framework and emphasis on evidence-based medicine support continued market penetration and technological advancement in radiopharmaceuticals and imaging equipment. Key growth catalysts include aging population demographics requiring advanced diagnostic tools, integration of hybrid imaging technologies, and expansion of therapeutic nuclear medicine applications.
  • NHS trusts are prioritizing nuclear medicine departments as part of cancer and cardiovascular care pathways, ensuring sustained investment.
  • The market is expected to benefit from emerging radiopharmaceuticals, increased training of nuclear medicine professionals, and enhanced reimbursement models that recognize the cost-effectiveness of nuclear medicine diagnostics..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • The UK nuclear medicine market will nearly double from $455.4M (2025) to $971.1M (2030), representing a 16.4% CAGR.
    • The UK's NHS-backed infrastructure and investment in advanced imaging technologies are primary growth catalysts for the market.
    • The UK is experiencing increased demand for targeted radiopharmaceuticals and personalized diagnostic solutions across major therapeutic areas.
    • The UK's regulatory environment and clinical expertise establish it as a European hub for nuclear medicine innovation and adoption.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    UK Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    UK: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES33.438.744.751.759.869.179.89215.5
    DIAGNOSTIC & IMAGING CENTERS92.3108.5127.6150.1176.5207.4243.7285.917.5
    HOSPITALS200232.1269.5313363.3421.5488.7565.816
    OTHER END USERS10.311.813.615.61820.723.827.315
    TOTAL336391455.4530.4617.5718.7835.9971.116.4

    Target Audience

    • NHS Trust Executives : Hospital administrators and procurement leaders need UK market data to justify capital investments in nuclear medicine equipment, plan departmental expansion, and align with national health priorities.
    • Medical Device Manufacturers : Equipment and radiopharmaceutical suppliers require detailed UK market intelligence to develop localized go-to-market strategies, understand NHS tender requirements, and forecast revenue potential.
    • Healthcare Investors : Private equity firms and healthcare investors need comprehensive UK market analysis to evaluate investment opportunities in nuclear medicine providers, technology companies, and service operators.
    • Clinical Professionals : Nuclear medicine physicians, radiologists, and technicians benefit from market insights to understand career opportunities, departmental funding trends, and emerging clinical applications in the UK.
    • Healthcare Consultants : Management consulting firms advising NHS trusts and healthcare organizations require UK-specific market data to develop strategic recommendations and support business case development.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK nuclear medicine market with detailed 2025-2030 forecasts, enabling accurate business planning and investment decisions tailored to the British healthcare landscape.
    • NHS Procurement Intelligence : Understand NHS funding patterns, procurement cycles, and investment priorities specific to nuclear medicine departments, helping suppliers and service providers align offerings with institutional buying behavior.
    • Competitive Landscape Analysis : Identify key players, market share dynamics, and competitive positioning within the UK nuclear medicine sector to inform strategic partnerships, acquisitions, and market entry strategies.
    • Regulatory & Reimbursement Insights : Gain clarity on UK-specific regulatory requirements, NICE guidance, and NHS reimbursement models that directly impact product adoption, pricing strategies, and market accessibility.
    • Growth Opportunity Mapping : Discover high-potential segments, emerging applications, and geographic hotspots within the UK market to prioritize resource allocation and identify first-mover advantages in underserved regions.

    Frequently asked questions

    What is the current size of the UK nuclear medicine market?

    The UK nuclear medicine market is valued at $455.4 million in 2025 and is projected to grow to $971.1 million by 2030.

    What is the growth rate of the UK nuclear medicine market?

    The UK nuclear medicine market is growing at a compound annual growth rate (CAGR) of 16.4% from 2025 to 2030.

    What factors are driving growth in the UK nuclear medicine market?

    Key drivers include NHS investment in advanced imaging infrastructure, rising demand for personalized medicine, increasing prevalence of chronic diseases, and expansion of radiopharmaceutical therapies in the UK.

    Which therapeutic areas are leading the UK nuclear medicine market?

    The UK nuclear medicine market is primarily driven by oncology, cardiology, and neurology applications, with growing adoption in targeted cancer therapies and cardiac imaging.

    How does the UK nuclear medicine market compare to Europe?

    The UK represents a significant portion of the European nuclear medicine market, with its advanced healthcare system and regulatory framework positioning it as a leader in innovation and clinical adoption.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status